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Cardiovascular safety trials of incretin-based
drugs: What do they mean?
Incretin-based dipeptidyl peptidase-4
inhibitors and glucagon-like peptide-1
receptor agonists are newer choices
of antidiabetic medications that are
now most widely used worldwide.
Preclinical study results suggest that
the two drugs potentially exert bene-
fits to prevent onsets and/or progres-
sions of diabetes-related
complications, such as myocardial
infarctions and strokes. Outcomes of
five clinical trials to evaluate the car-
diovascular (CV) safety of dipeptidyl
peptidase-4 inhibitors and glucagon-
like peptide-1 receptor agonist have
been recently reported. The heart fail-
ure findings of the Saxagliptin Assess-
ment of Vascular Outcomes Recorded
in Patients with Diabetes Mellitus-
Thrombolysis in Myocardial Infarction
53 (SAVOR-TIMI53) are unexpected
and very concerning; results of the
Examination of Cardiovascular Out-
comes with Alogliptin vs Standard of
Care (EXAMINE), the Trial Evaluating
Cardiovascular Outcomes with Sita-
gliptin (TECOS) and the Evaluation of
Lixisenatide in Acute Coronary Syn-
drome (ELIXA) encourage neutral CV
safety profiles of incretin-based drugs
in individuals with type 2 diabetes
and established CV diseases or multi-
ple CV risks. Furthermore, the Liraglu-
tide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome
Results (LEADER) results show the
benefits of liraglutide in preventing
CV events in a similar study popula-
tion. Despite the many preclinical
studies showing the beneficial effects
of incretin-related drugs, most CV
safety trials of incretin-based drugs,
except for LEADER, did not show ben-
efits for CV events. It is important to
recognize that CV safety trials were
carried out to meet the US Food and
Drug Administration guidance to
assess CV safety of all new antidia-
betic drugs; they were not designed
to assess their benefits for CV events.
Therefore, the long-term potential
benefit, as well as even the safety, of
incretin-based drugs for certain CV
outcomes has not been definitively
established, and requires evaluation in
more specific and more relevant trials.
If the need for CV safety trials would
be determined based on an individual
drug’s safety data during its earlier
development as well as its mechanism
of action, resources could be saved
for carrying out such clinical trials.
Chronic hyperglycemia, in collaboration
with hypertension and dyslipidemia, can
cause diabetes-associated microvascular
complications (e.g., neuropathy, nephropa-
thy and retinopathy) and macrovascular
complications (e.g., myocardial infarc-
tions, strokes and peripheral arterial dis-
eases) in individuals with diabetes. Lines
of evidence show that amelioration of
glycemia with appropriate controls of
bodyweight, blood pressures, and lipid
levels prevents onset and/or progression
of such complications. To date, several
glucose-lowering drugs have been
developed to normalize glycemia in indi-
viduals with type 2 diabetes. Among
such drugs, incretin-based dipeptidyl
peptidase-4 inhibitors (DPP-4is) and glu-
cagon-like peptide-1 receptor agonists
(GLP-1RAs) are newer choices of such
antidiabetic medications. The two drugs
are now most widely used worldwide, in
part because they have low risks of hypo-
glycemia and bodyweight gain despite
their ability to ameliorate glycemia
through enhancement of insulin secre-
tion, unlike sulfonylureas and glinides1.
DPP-4is improve glycemic control in
individuals with type 2 diabetes by pre-
venting degradation of the two incretins,
glucagon-like peptide-1 (GLP-1) and glu-
cose-dependent insulinotropic polypep-
tide. GLP-1RAs does so by binding to
the GLP-1 receptor and activating GLP-1
receptor signaling. GLP-1 and glucose-
dependent insulinotropic polypeptide are
secreted from the intestine on ingestion
of various nutrients and enhance insulin
secretion from pancreatic b-cells glucose-
dependently. Preclinical studies in animal
models have shown diverse biological
functions of both incretins in addition to
their glucose-dependent insulinotropic
action2. Thus, it has been expected that
the incretin-related drugs potentially
exert beneﬁts to prevent onsets and/or
progressions of diabetes-related complica-
tions, such as myocardial infarctions
(MI) and strokes. However, the effects of
incretin-based drugs on diabetes-related
complications need to be examined in
clinical trials with adequately powered,
prospective, controlled relevant end-
points. For these reasons, outcomes of
ﬁve clinical trials to evaluate the cardio-
vascular (CV) safety of individual incre-
tin-based drugs have gained much
attention.
Three trials, the Saxagliptin Assess-
ment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus-Throm-
bolysis in Myocardial Infarction 53
(SAVOR-TIMI53), the Examination of
Cardiovascular Outcomes with Alogliptin
vs Standard of Care (EXAMINE) and
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the Trial Evaluating Cardiovascular Out-
comes with Sitagliptin (TECOS), assessed
CV safety of the DPP-4is saxagliptin, alo-
gliptin and sitagliptin in individuals with
type 2 diabetes at risk for CV events,
respectively. SAVOR-TIMI53 was carried
out globally using a total of 16,492
patients with a history of CV disease (ap-
proximately 80% of the study population)
or with multiple CV risks (approximately
20%) (Table 1)3. The median observation
period was 2.1 years; glycated hemoglo-
bin (HbA1c) changes from baseline were
just 0.3% greater in those receiving saxa-
gliptin compared with a placebo. The
primary composite end-point of CV
death, non-fatal MI and non-fatal
ischemic stroke occurred in patients
receiving saxagliptin similarly to those
receiving a placebo (hazard ratio [HR]
1.00, 95% conﬁdence interval [CI] 0.89–
1.12, P = 0.99). EXAMINE was carried
out globally using a total of 5,380
patients, all of whom had acute coronary
syndrome4. The median observation per-
iod was 1.6 years; HbA1c changes from
baseline were 0.4% greater in those
receiving alogliptin. The primary com-
posite end-point of CV death, non-fatal
MI and non-fatal stroke occurred in
patients receiving alogliptin similarly to
those receiving a placebo (HR 0.96,
upper 99% CI: <1.16, P = 0.32). TECOS
was carried out globally using a total of
14,671 patients with a history of CV dis-
ease (approximately 75%), ischemic
stroke (approximately 25%) and/or
peripheral artery diseases (approximately
20%)5. The median observation period
was 3.0 years; HbA1c changes from base-
line were 0.3% greater in those receiving
sitagliptin. The primary composite end-
point of CV death, non-fatal MI, non-
fatal stroke and hospitalization for unsta-
ble angina was 0.98 (95% CI: 0.89–1.08,
P = 0.65). These results can be taken to
show that DPP-4is have neutral CV
safety proﬁles in individuals with type 2
diabetes and high risks for CV events,
particularly MI, stroke and CV death.
Unexpectedly, saxagliptin use was associ-
ated with a signiﬁcant increase in hospi-
talization for heart failure compared with
a placebo (HR 1.27, 95% CI: 1.07–1.51,
P = 0.007). EXAMINE and TECOS did
not ﬁnd signiﬁcant associations of heart
failure with use of alogliptin and sitaglip-
tin, suggesting that the effects of saxaglip-
tin on heart failure might be a drug
effect rather than a class effect. Rigorous
post-hoc analyses on SAVOR-TIMI53
failed to identify obvious causal mecha-
nisms for heart failure with saxagliptin;
further investigations are warranted to
evaluate changes in cardiac function in
individuals with type 2 diabetes receiving
saxagliptin.
Two clinical trials, the Evaluation of
Lixisenatide in Acute Coronary Syn-
drome (ELIXA) and the Liraglutide
Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results
(LEADER), assessed the CV safety of the
GLP-1RAs lixisenatide and liraglutide in
individuals with type 2 diabetes at risk
for CV events, respectively. ELIXA was
carried out globally using a total of 6,068
patients with a recent experience of acute
coronary syndrome (Table 1)6. The med-
ian observation period was 2.1 years;
HbA1c changes from baseline were
approximately 0.3% greater in those
receiving lixisenatide compared with a
placebo. The primary composite end-
point of CV death, non-fatal MI, non-
fatal stroke and hospitalization for unsta-
ble angina occurred in patients receiving
lixisenatide similarly to those receiving
placebo (HR 1.02, 95% CI: 0.89–1.17,
P = 0.81). LEDER was carried out glob-
ally using a total of 9,340 patients with
high risks for CV events7. The median
observation period was 3.8 years; HbA1c
changes from baseline were approxi-
mately 0.4% greater in those receiving
liraglutide compared with a placebo. The
primary composite end-point of CV
death, non-fatal MI and non-fatal stroke
occurred in signiﬁcantly fewer patients
receiving liraglutide (HR 0.87, 95% CI:
0.78–0.97, P < 0.001 for non-inferiority
and P = 0.01 for superiority). Although
the differing outcomes of ELIXA and
LEADER are still unexplained, differences
in baseline characteristics of the enrolled
patients, such as HbA1c (LEADER
8.7%/ELIXA 7.7%) and body mass
index (LEADER 32/ELIXA 30),
might have implications in accord with
differences in the mode of action (i.e.,
short-acting vs long-acting)8. Further
investigations are required to understand
the factors responsible for the differing
outcomes of ELIXA and LEADER. Nev-
ertheless, it is important to consider that
hospitalization for heart failure was not
affected by lixisenatide use (HR 0.96,
95% CI: 0.75–1.23, P = 0.75) or by
liraglutide use (HR 0.87, 95% CI: 0.73–
1.05, P = 0.14).
The heart failure ﬁndings of SAVOR-
TIMI53 are unexpected and very con-
cerning; the results of EXAMINE,
TECOS and ELIXA encourage neutral
CV safety proﬁles of incretin-based drugs
in individuals with type 2 diabetes and
established CV diseases or multiple CV
risks. Furthermore, LEADER results
show beneﬁts of liraglutide for preventing
CV events in a similar study population.
Because of the existence of the many
preclinical studies showing the beneﬁcial
effects of incretins and incretin-related
drugs, obvious questions arise as to why
most CV safety trials of incretin-based
drugs, except for liraglutide, did not show
beneﬁts for CV events. In this regard, it
is important to recognize that CV safety
trials were carried out to meet the US
Food and Drug Administration guidance
implemented in 2008 to assess the CV
safety of all new antidiabetic drugs; they
were not designed to assess their beneﬁts
for CV events. CV safety trials require a
large study population in multiple coun-
tries to obtain CV events sufﬁcient for
statistical analysis. Monitoring such large
study populations globally requires sub-
stantial costs and efforts; thus encourag-
ing enrollment of patients with
established CV diseases who are likely to
experience a CV event within a limited
time-period. These patients are already
taking aspirin, statin and angiotensin-
converting enzyme inhibitors/angiotensin
II receptor blockers along with multiple
antidiabetic drugs (Table 1); the results
obtained should be evaluated taking these
patient characteristics into consideration.
Therefore, the long-term potential bene-
ﬁt, as well as even the safety, of incretin-
based drugs for certain CV outcomes has
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not been deﬁnitively established and
requires evaluation of individuals without
CV diseases, similar to what was done in
the United Kingdom Prospective Dia-
betes Study (UKPDS)9, making full use
of appropriate surrogate markers (e.g.,
intima-media thickness on the carotid
ultrasonography). In this respect, the
question remains whether the US Food
and Drug Administration guidance for
assessing CV safety through large CV
safety trials of every new antidiabetes
drug is appropriate. If the need for CV
safety trials would be determined based
on an individual drug’s safety data dur-
ing its earlier development as well as its
mechanism of action, resources could be
saved for carrying out more speciﬁc and
more relevant trials (e.g., prevention of
onset and/or progression of diabetes-
related micro- and macrovascular com-
plications) or trials to ﬁnd effective thera-
peutics for reducing CV death and
improving long-term healthy survival.
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